A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Efmarodocokin alfa (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Genentech; Roche
- 28 Sep 2023 Status changed from completed to discontinued.
- 23 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 19 Dec 2022 This trial has been Discontinued at Hungary location, According to Eudra record.